Vaccines need to be studied to assess effectiveness against new variants of the coronavirus

Coronavirus artwork
Date published

The American pharmaceutical company Novavax has released results about the efficacy of its vaccine - claiming it's 95 per cent effective against the original version of Covid-19.

But it's less effective against the fast-spreading variant of the virus that's now become dominant in South Africa. Hear the interview